UMPS
Uridine 5'-monophosphate synthase
As of the edition of 20 October 2026, UMPS (uridine 5'-monophosphate synthase, UniProt P11172) has 2 drugs tested at it and 2 companies on the list, 0 on route A and 2 on route B.
Sources: UniProt, ClinicalTrials.gov, ChEMBL, FDA Orange Book and Purple Book, Pharos.
The protein
- UniProt
- P11172
- How well studied
- Drug target: an approved drug acts on it
- Solved structures
- 125
- Disease areas
- Cancer; Digestive system; Skin and connective tissue; Hormones; Mouth and teeth; Chemically induced; Ear, nose and throat; Lungs and airways
- Registered trials of its drugs
- 53
Drugs at this target
| Status | Count |
|---|---|
| Marketed | 1 |
| Withdrawn from market | 1 |
| Total | 2 |
| Drug | Status | Furthest phase | US protection |
|---|---|---|---|
| Oteracil | Marketed | Phase 3 | none listed |
| Azaribine | Withdrawn from market | No phase stated | none listed |
2 of 2 drugs, the most tested first.
Companies at this target
| Where the company stands | Companies |
|---|---|
| Route B | 2 |
| Total on the list | 2 |
The other 0 companies at UMPS
In the product2 companies in all; 0 are not named here, and no score is.
See the 2 companies at UMPS, ranked, with the facts behind eachRequest access. Nothing is shown until you do.